LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Inicio・Lista de Acciones・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Cerrado

SectorSanidad

11.8 -0.59

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

11.28

Máximo

11.87

Métricas clave
By Trading Economics
Ingresos	227M
Ventas	139M
P/B Media del Sector	4.506 49.701
Margen de beneficios	163.843
Empleados	1,796
EBITDA	1.3M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+65.84% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.1B
Apertura anterior	12.39
Cierre anterior	11.8

Noticias sobre sentimiento de mercado

By Acuity

10%

90%

10 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

14.24 / 14.78 Soporte y Resistencia

Hutchison China MediTech Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

20 may 2026, 23:31 UTC

Acciones populares

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 may 2026, 22:52 UTC

Principales Movimientos del Mercado

Osisko Shares Fall on Planned Convertible Notes Offering

20 may 2026, 23:47 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 may 2026, 23:44 UTC

Ganancias

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 may 2026, 23:35 UTC

Charlas de Mercado

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 may 2026, 23:30 UTC

Charlas de Mercado

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 may 2026, 23:17 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

20 may 2026, 23:17 UTC

Charlas de Mercado

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 may 2026, 23:15 UTC

Charlas de Mercado

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 may 2026, 23:14 UTC

Ganancias

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 may 2026, 23:02 UTC

Charlas de Mercado

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 may 2026, 22:57 UTC

Charlas de Mercado

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 may 2026, 22:57 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

20 may 2026, 22:57 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

20 may 2026, 22:51 UTC

Charlas de Mercado

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 may 2026, 22:51 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 may 2026, 22:27 UTC

Charlas de Mercado

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 may 2026, 22:14 UTC

Charlas de Mercado

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 may 2026, 22:10 UTC

Ganancias

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 may 2026, 22:00 UTC

Ganancias

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 may 2026, 21:38 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 may 2026, 21:27 UTC

Ganancias

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 may 2026, 21:20 UTC

Ganancias

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 may 2026, 21:19 UTC

Ganancias

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 may 2026, 21:18 UTC

Ganancias

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 may 2026, 21:17 UTC

Ganancias

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 may 2026, 21:17 UTC

Ganancias

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 may 2026, 21:17 UTC

Ganancias

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 may 2026, 21:16 UTC

Ganancias

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR previsión

Precio Objetivo

By TipRanks

65.84% repunte

Estimación a 12 Meses

Media 20 USD 65.84%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

14.24 / 14.78Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimiento

By Acuity

10 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.